Taysha gene therapies provides update on tsha-120 program in giant axonal neuropathy and a 2023 corporate outlook

Type b end-of-phase 2 meeting with u.s. food and drug administration (fda) provided additional clarity for tsha-120 for the treatment of giant axonal neuropathy (gan) ultra-rare disease program  - fda acknowledged mfm32 as an acceptable endpoint with a recommendation to dose additional patients in a double-blind, placebo-controlled design to support biologics license application (bla) submission
TSHA Ratings Summary
TSHA Quant Ranking